, moyenne (±DS) 18-30 ans, n (%) 30-40 ans, n(%) 40-50 ans, n(%) 50-60 ans, n(%) >60 ans, n(%), 0%) Age (années), vol.60
, Lignes directrices pour le dépistage, la prévention et le traitement de l'ostéoporose après greffe de cellules souches hématopoïétiques chez l'adulte selon McClune et al, Annexe, vol.4
, Algorithme de gestion pour les patients subissant une allogreffe de CSH selon l'opinion d'un expert, Annexe, vol.5
,
Ostéoporoses secondaires. Définitions et conduite diagnostique, Rev Rhum, vol.68, pp.669-77, 2001. ,
Understanding the burden of osteoporosis and use of the World Health Organization FRAX, Orthopedics, vol.35, pp.798-805, 2012. ,
, EMC -AKOS, vol.2010, pp.1-12
Epidemiology of osteoporosisrelated fractures in France: a literature review, Joint Bone Spine, vol.77, pp.546-51, 2010. ,
Osteoporosis in young adults: pathophysiology, diagnosis, and management, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.23, pp.2735-2783, 2012. ,
Actualisation 2018 des recommandations françaises du traitement de l'ostéoporose post-ménopausique, Rev Rhum, vol.85, pp.428-468, 2018. ,
Ostéoporoses : généralités, stratégie diagnostique, EMC -Appar Locomoteur, vol.7, issue.2, pp.1-5, 2012. ,
Le remodelage osseux normal et pathologique, Rev Francoph Lab, vol.2012, pp.33-42, 2012. ,
Mechanisms of osteoporosis after hematopoietic cell transplantation, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.6, pp.165-74, 2000. ,
Les différents types d'ostéoporose et leurs stratégies thérapeutiques, Actual Pharm, vol.54, pp.18-22, 2015. ,
Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases, JAMA, vol.292, pp.490-495, 2004. ,
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell, vol.93, pp.165-76, 1998. ,
Osteoclast differentiation and activation, Nature, vol.423, pp.337-379, 2003. ,
, Writing Group for the ISCD Position Development Conference. Diagnosis of osteoporosis in men, premenopausal women, and children, J Clin Densitom Off J Int Soc Clin Densitom, vol.7, pp.17-26, 2004.
Use of Trabecular Bone Score (TBS) as a Complementary Approach to Dual-energy X-ray Absorptiometry (DXA) for Fracture Risk Assessment in Clinical Practice, J Clin Densitom Off J Int Soc Clin Densitom, vol.20, pp.334-379, 2017. ,
Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.16, pp.403-413, 2005. ,
Les apports de la DXA en dehors de la mesure de la densité minérale osseuse, Rev Rhum, vol.80, pp.225-255, 2013. ,
Risk factors for osteoporosis related to their outcome: fractures, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.12, pp.630-638, 2001. ,
Les médicaments de l'ostéoporose ,
A reference standard for the description of osteoporosis, Bone, vol.42, pp.467-75, 2008. ,
International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions, Bone, vol.43, pp.1115-1136, 2008. ,
Ostéoporose : critères de diagnostic et de suivi. L'outil FRAX®. Scores radiologiques, Rev Rhum Monogr, vol.77, pp.167-72, 2010. ,
Prise en charge de l'ostéoporose, 2006. ,
Place actuelle de l'ostéodensitométrie, Rev Rhum, vol.83, pp.264-270, 2016. ,
Adjusting FRAX® on TBS for identification of subjects at high risk of fractures, Bone, vol.101, pp.214-222, 2017. ,
Actualisation 2014 des recommandations sur la prévention et le traitement de l'ostéoporose cortico-induite, Rev Rhum, vol.81, pp.385-94, 2014. ,
The Trabecular Bone Score (TBS) Complements DXA and the FRAX as a Fracture Risk Assessment Tool in Routine Clinical Practice, Curr Osteoporos Rep, vol.15, pp.521-552, 2017. ,
Riskequivalent T-score adjustment for using lumbar spine trabecular bone score (TBS): the Manitoba BMD registry, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.29, pp.751-759, 2018. ,
, Tbs in routine clinical practice: proposals of use
Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice, Bone, vol.78, pp.216-240, 2015. ,
Utility of the trabecular bone score (TBS) in secondary osteoporosis, Endocrine, vol.47, pp.435-483, 2014. ,
Allogreffe de cellules souches hématopoïétiques : réalisation et complications, EMC -Hématologie, vol.2010, pp.1-19 ,
Allogreffe de cellules souches hématopoïétiques Partie 1, Hématologie, vol.19, pp.288-96, 2013. ,
Allogreffes de cellules souches hématopoïétiques, Transfus Clin Biol, vol.18, pp.235-280, 2011. ,
Sequential Conditioning with Thiotepa in T Cell-Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.24, pp.1013-1034, 2018. ,
Place de l'allogreffe de cellules souches hématopoïétiques dans le traitement des hémopathies malignes de l'adulte, Rev Francoph Lab, pp.45-50, 2007. ,
Cellules souches périphériques: une nouvelle approche des greffes de moelle osseuse, Rev Fr Lab, pp.49-53, 1998. ,
Greffes de cellules souches hématopoïétiques à partir d'un donneur haplo-identique : recommandations de la SFGM-TC (première partie), Pathol Biol, vol.62, pp.180-184, 2014. ,
Greffes de cellules souches hématopoïétiques à partir d'un donneur haploidentique : recommandations de la SFGM-TC (deuxième partie), Pathol Biol, vol.62, pp.185-194, 2014. ,
La maladie chronique du greffon contre l'hôte, Hématologie, vol.16, pp.420-429, 2010. ,
Allogreffe de cellules souches hématopoïétiques Partie 2, Hématologie, vol.19, pp.342-349, 2013. ,
Maladie de Greffon contre l'hôte (GVH) : clinique, Hématologie, vol.19, pp.28-37, 2013. ,
Prise en charge de la maladie du greffon contre l'hôte chronique : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC), Bull Cancer, vol.104, pp.145-68, 2017. ,
Étude du chimérisme après allogreffe de cellules hématopoïétiques : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC), Bull Cancer, vol.104, pp.59-64, 2017. ,
Recommandations de la SFGM-TC concernant l'injection prophylactique, préemptive et curative des lymphocytes du donneur (DLI) après allogreffe de cellules souches hématopoïétiques, Pathol Biol, vol.62, pp.193-199, 2014. ,
Osteoporosis after transplantation, Curr Osteoporos Rep, vol.10, pp.48-55, 2012. ,
Post-transplantation osteoporosis, Arq Bras Endocrinol Metabol, vol.54, pp.143-152, 2010. ,
Pilot study on the use of zoledronic acid to prevent bone loss in allo-SCT recipients, Bone Marrow Transplant, vol.44, pp.35-41, 2009. ,
Bone loss following hematopoietic stem cell transplantation: a long-term follow-up, Blood, vol.103, pp.3635-3678, 2004. ,
Factors influencing the late phase of recovery after bone mineral density loss in allogeneic stem cell transplantation survivors, Bone Marrow Transplant, vol.51, pp.1101-1107, 2016. ,
Bone loss and its management in long-term survivors from allogeneic stem cell transplantation, J Clin Endocrinol Metab, vol.92, pp.4536-4581, 2007. ,
Allogeneic bone marrow transplantation is associated with a preferential femoral neck bone loss, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.12, pp.880-886, 2001. ,
High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy, Bone Marrow Transplant, vol.41, pp.393-401, 2008. ,
Bone metabolism in patients more than five years after bone marrow transplantation, Bone Marrow Transplant, vol.34, pp.491-497, 2004. ,
Bone management in hematologic stem cell transplant recipients, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.29, pp.2597-610, 2018. ,
Increased incidence of fractures in recipients of hematopoietic stem-cell transplantation, J Clin Oncol Off J Am Soc Clin Oncol, vol.33, pp.1364-70, 2015. ,
Osteoporosis after stem cell transplantation, Curr Osteoporos Rep, vol.11, pp.305-315, 2013. ,
Mechanism and Treatment Strategy of Osteoporosis after Transplantation, Int J Endocrinol, p.280164, 2015. ,
Bone mineral density after allogeneic bone marrow transplantation, Bone Marrow Transplant, vol.24, pp.885-894, 1999. ,
Osteoimmunology and its implications for transplantation, Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg, vol.13, pp.2245-54, 2013. ,
The role of cytokines in the changes in bone turnover following bone marrow transplantation, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.13, pp.62-70, 2002. ,
Biomarkers of bone and mineral metabolism following bone marrow transplantation, Adv Clin Chem, vol.49, pp.99-120, 2009. ,
Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism, Bone, vol.39, pp.1352-60, 2006. ,
Post-transplantation osteoporosis, Endocrinol Metab Clin North Am, vol.36, pp.937-963, 2007. ,
Longlasting bone damage detected by dual-energy x-ray absorptiometry, phalangeal osteosonogrammetry, and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation, J Clin Endocrinol Metab, vol.87, pp.5058-65, 2002. ,
Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients, Bone Marrow Transplant, vol.46, pp.1-9, 2011. ,
Strategies to reduce toxicities and improve outcomes in renal transplant recipients, Pharmacotherapy, vol.22, pp.316-344, 2002. ,
Approach to the patient with transplantation-related bone loss, J Clin Endocrinol Metab, vol.94, pp.1483-90, 2009. ,
High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: a mechanism for post-bone marrow transplantation osteopenia, Cancer, vol.92, pp.2419-2447, 2001. ,
Glucocorticoid-Induced Bone Disease, N Engl J Med, vol.365, pp.62-70, 2011. ,
Complications ostéoarticulaires des transplantations d'organe, EMC -Appar Locomoteur, pp.1-7, 2007. ,
, EMC -Appar Locomoteur, vol.2011, pp.1-10
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.13, pp.777-87, 2002. ,
Immunosuppression and bone loss after transplantation, Transplant Proc, vol.33, pp.3665-3672, 2001. ,
Osteoporosis after solid organ and bone marrow transplantation ,
, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.14, pp.617-647, 2003.
Glucocorticoid-induced osteoporosis: management update, Curr Osteoporos Rep, vol.8, pp.10-14, 2010. ,
A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin, Bone Marrow Transplant, vol.23, pp.355-61, 1999. ,
Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.14, pp.1013-1022, 2003. ,
Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate, J Clin Endocrinol Metab, vol.90, pp.3877-85, 2005. ,
Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation, Bone Marrow Transplant, vol.37, pp.81-89, 2006. ,
Pamidronate reduces bone loss after allogeneic stem cell transplantation, J Clin Endocrinol Metab, vol.91, pp.3835-3878, 2006. ,
Intermittent zoledronic Acid prevents bone loss in adults after allogeneic hematopoietic cell transplantation, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.19, pp.1361-1368, 2013. ,
Ibandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: a randomized-controlled trial, BoneKEy Rep, vol.5, p.843, 2016. ,
Suivi et prise en charge des troubles endocriniens en post-greffe de cellules souches hématopoïétiques : insuffisance corticotrope et ostéoporose, Pathol Biol, vol.61, pp.171-174, 2013. ,
Consommation des traitements antiostéoporotiques et incidence des fractures ostéoporotiques en France entre 2014 et 2016 : une prise en charge médicamenteuse insuffisante, Rev Rhum, vol.86, pp.387-92, 2019. ,
Bone density consequences of initiation and compliance with therapy for osteoporosis, Arthritis Care Res, vol.62, pp.1440-1445, 2010. ,
, Os brisés, vies brisées : une feuille de route pour résoudre la crise des fractures de fragilité en France
Fracture liaison service: impact on subsequent nonvertebral fracture incidence and mortality, J Bone Joint Surg Am, vol.96, p.29, 2014. ,
Bone loss in long-term survivors after transplantation of hematopoietic stem cells: a prospective study, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.11, pp.344-53, 2000. ,
Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.7, pp.257-64, 2001. ,
Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation, J Bone Miner Res Off J Am Soc Bone Miner Res, vol.14, pp.342-50, 1999. ,
Impact of circulating bone-resorbing cytokines on the subsequent bone loss following bone marrow transplantation, Bone Marrow Transplant, vol.34, pp.89-94, 2004. ,
Prospective assessment of bone turnover and clinical bone diseases after allogeneic hematopoietic stem-cell transplantation, Transplantation, vol.89, pp.1354-61, 2010. ,
Accelerated bone mass senescence after hematopoietic stem cell transplantation, Transl Med UniSa, vol.5, pp.7-13, 2013. ,
Changes in trabecular bone score and bone mineral density following allogeneic hematopoietic stem cell transplantation, Bone, vol.124, pp.40-46, 2019. ,
Chapitre29 -Leucémies chroniques: Traitement de la leucémie myéloïde chronique, Association nationale des enseignants de pharmacie clinique, pp.247-266, 2016. ,
Frequency of abnormal findings detected by comprehensive clinical evaluation at 1 year after allogeneic hematopoietic cell transplantation, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.15, pp.416-436, 2009. ,
The impact of glucocorticoid therapy on trabecular bone score in older women, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.26, pp.1773-80, 2015. ,
Bone status in glucocorticoid-treated men and women ,
, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.27, pp.39-48, 2016.
Spine bone texture assessed by trabecular bone score (TBS) predicts osteoporotic fractures in men: the Manitoba Bone Density Program, Bone, vol.67, pp.10-14, 2014. ,
Comparing bone microarchitecture by trabecular bone score (TBS) in Caucasian American women with and without osteoporotic fractures, Calcif Tissue Int, vol.95, pp.201-209, 2014. ,
Lumbar spine texture enhances 10-year fracture probability assessment, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.25, pp.2271-2278, 2014. ,
Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study, J Bone Miner Res Off J Am Soc Bone Miner Res, vol.26, pp.2762-2771, 2011. ,
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation, N Engl J Med, vol.363, pp.2091-101, 2010. ,
Increased risk of bone loss without fracture risk in long-term survivors after allogeneic stem cell transplantation, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.13, pp.517-537, 2007. ,
Risk of osteoporosis and pathologic fractures in cancer patients who underwent hematopoietic stem cell transplantation: a nationwide retrospective cohort study, Oncotarget, vol.8, pp.34811-34820, 2017. ,
Glucocorticoid-induced osteoporosis: an update, Endocrine, vol.61, pp.7-16, 2018. ,
Fracture risk prediction using FRAX in patients following hematopoietic stem cell transplantation, Arch Osteoporos, vol.13, p.38, 2018. ,
Mycophenolate mofetil: a promising new immunosuppressant that does not cause bone loss in the rat, Transplantation, vol.65, pp.275-283, 1998. ,
Relationship between immunosuppression and osteoporosis in an outpatient liver transplant clinic, Transplant Proc, vol.37, pp.1910-1911, 2005. ,
Osteoporosis and related risk factors in renal transplant recipients, Transplant Proc, vol.41, pp.2820-2822, 2009. ,
Accelerated bone mineral density loss occurs with similar incidence and severity, but with different risk factors, after autologous versus allogeneic hematopoietic cell transplantation, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.16, pp.1130-1137, 2010. ,
Glucocorticoid-induced osteoporosis: pathophysiology and therapy, Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA, vol.18, pp.1319-1347, 2007. ,
Prevention and treatment of bone loss and fractures in patients undergoing a hematopoietic stem cell transplant: a systematic review and meta-analysis, Bone Marrow Transplant, vol.52, pp.663-70, 2017. ,
Bone disease after transplantation: osteoporosis and fractures risk, Arq Bras Endocrinol Metabol, vol.58, pp.484-92, 2014. ,
Metabolic bone diseases in patients after allogeneic hematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease, Transpl Int Off J Eur Soc Organ Transplant, vol.24, pp.867-79, 2011. ,
Bone loss and avascular necrosis of bone after hematopoietic cell transplantation, Semin Hematol, vol.49, pp.59-65, 2012. ,
,
, Rinsho Ketsueki, vol.55, pp.607-639, 2014.
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.21, pp.1167-87, 2015. ,
Transplantation osteoporosis, Arq Bras Endocrinol Amp Metabol, vol.50, pp.783-92, 2006. ,
Reproductive issues in patients undergoing Hematopoietic Stem Cell Transplantation: an update, J Ovarian Res, vol.9, p.72, 2016. ,
Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation, J Clin Endocrinol Metab, vol.90, pp.627-661, 2005. ,